Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer

被引：0
|
作者：
Goyal, R. K.
Carter, G. C.
Nagar, S. N.
Smyth, E. N.
Price, G. L.
Huang, Y-J
Bromund, J. L.
Li, L.
Schilder, J. M.
Davis, K. L.
Kaye, J. A.
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] RTI Hlth Solut, Waltham, MA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-08-19
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [22] Comparison of healthcare resource utilization and costs in women with HR+/HER2-metastatic breast cancer treated with ribociclib vs palbociclib or abemaciclib
    Balu, Sanjeev
    Burne, Rebecca
    Guerin, Annie
    Bungay, Rebecca
    Paul, Mary Lisha
    Sin, Roxana
    CANCER RESEARCH, 2021, 81 (04)
  • [23] Identifying drivers of first-line HR+/HER2-metastatic breast cancer treatment choices
    Brufsky, Adam
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Kurosky, Samantha K.
    Arruda, Lillian Shahied
    Heck, Wendy
    Cha-Silva, Ashley S.
    FUTURE ONCOLOGY, 2024, 20 (29) : 2165 - 2177
  • [24] Current Treatment Patterns Among Postmenopausal Women with HR+/HER2-Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
    Goldschmidt, Deborah
    Dalal, Anand A.
    Romdhani, Hela
    Kelkar, Sneha
    Guerin, Annie
    Gauthier, Genevieve
    Wu, Eric Q.
    Niravath, Polly
    Small, Tania
    ADVANCES IN THERAPY, 2018, 35 (04) : 482 - 493
  • [25] VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA
    Chin, A.
    Ip, Q.
    Wu, X.
    Lyle, D.
    VALUE IN HEALTH, 2024, 27 (06) : S163 - S163
  • [26] Identifying Drivers of First-Line HR+/HER2-Metastatic Breast Cancer Treatment Choices
    Brufsky, Adam M.
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Cha, Ashley S.
    Arruda, Lillian Shahied
    Heck, Wendy
    Kurosky, Samantha K.
    CANCER RESEARCH, 2023, 83 (05)
  • [27] Patient and treatment characteristics in HR+/HER2-metastatic breast cancer in a real-life setting
    Karadurmus, Nuri
    Sendur, Mehmet Ali Nahit
    Cil, Timucin
    Oksuzoglu, Omur Berna Cakmak
    Arslan, Cagatay
    Harputluoglu, Hakan
    Goksu, Sema Sezgin
    Ozturk, Banu
    MevludeInanc
    Cubukcu, Erdem
    Demirci, Umut
    Erdem, Dilek
    Cihan, Sener
    Tural, Deniz
    Dumludag, Aysegul
    Yilmaz, Funda
    Avsar, Esin
    Sonusen, Sermin Dinc
    Ozturk, Ozge Fulya
    Aver, Birkan
    Kaplan, Muhammet Ali
    CANCER RESEARCH, 2023, 83 (05)
  • [28] The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2-metastatic breast cancer
    Ovcaricek, Tanja
    Matos, Erika
    Borstnar, Simona
    Ribnikar, Domen
    Kuhar, Cvetka Grasic
    Cankar, Kaja
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Everolimus-based combination therapies for HR+, HER2-metastatic breast cancer
    O'Shaughnessy, Joyce
    Beck, J. Thaddeus
    Royce, Melanie
    CANCER TREATMENT REVIEWS, 2018, 69 : 204 - 214
  • [30] Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer
    Li, Nanxin
    Du, Ella X.
    Chu, Lihao
    Peeples, Miranda
    Xie, Jipan
    Barghout, Victoria
    Tang, Derek H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1167 - 1178
12345